Abstract Library

#3476 A phase II single arm trial evaluating the efficacy and safety of Temozolomide for second-line treatment of neuroendocrine carcinomas progressing after first-line platinum-based therapy

Introduction: Second-line treatment for neuroendocrine carcinoma (NEC) have been investigated in prospective trials, with only few prospective trials ongoing. Therefore, there is no consensus on the second-line regimen to use in patients with progressive NEC. These patients have generally a poor performance status (PS) and the tolerance to combination therapy is low. Metronomic temozolomide showed, in retrospective trials, a good safety and efficacy profile.

Conference:

Presenting Author:

Authors: Cannella L, von Arx C, Bracigliano A, Pizzolorusso A, Antonella D,

Keywords: neuroendocrine, temozolomide, NEC, Treatment,

#3373 Educational learning investigational observational study (ELIOS): A 10-year Italian network to standardize procedures and obtain multicentric clinical research studies

Introduction: Neuroendocrine neoplasms (NEN) are heterogeneous tumors with peculiar biology and rising incidence. Multidisciplinary approach in skilled centers is required to manage these patients. Accurate and complete data are indispensable for high quality epidemiological and clinical research.

Conference:

Presenting Author:

Authors: Modica R, Tafuto S, Riccardi F, Di Sarno A, Rodriquenz M,

Keywords: neuroendocrine, research, network,

#2194 Therapeutic Sequences in Patients with G1-G2 Neuroendocrine Tumors (NETs): An Observational, Multicentre, Prospective/Retrospective Study

Introduction: Many different therapies are suggested by guidelines to treat loco-regionally advanced or metastatic G1-G2 neuroendocrine tumors (NETs). However, a precise therapeutic algorithm has not yet been established.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author:

Authors: Faggiano A, Di Maio S, Tafuto S, Mocerino C, Di Sarno A,

Keywords: neuroendocrine tumor, medical therapy, sequence of treatments,

#725 Contrast-Enhanced Ultrasonography (CEUS) Predicts the Effectiveness of Anti-Angiogenic Therapies in Patients with Liver Metastases from Neuroendocrine Tumors

Introduction: Liver metastases (LM) from neuroendocrine tumors (NETs) exhibit a typical hypervascular pattern in the arterial phase on CEUS, allowing for a differential diagnosis between NET and non-NET LM. Medical therapy includes agents acting on angiogenesis and vascularization which may result in a change in CEUS findings.

Conference: 10th Annual ENETSConcerence (2013)

Presenting Author: Di Sarno A

Authors: Di Sarno A, Del Prete M, Marotta V, De Stefano G, Marciello F,

Keywords: neuroendocrine tumor, liver metastases, CEUS, contrast enhancement, predictive factor of response,

#724 Contrast-Enhanced Ultrasonography (CEUS) Reliably Predicts Tumor Progression in Pancreatic Neuroendocrine Tumors

Introduction: Neuroendocrine tumors (NETs) exhibit a typical vascular pattern in the arterial phase on CEUS. The role of CEUS in the prognostic evaluation of pancreatic NET (pNET) has been poorly investigated.

Conference: 10th Annual ENETSConcerence (2013)

Presenting Author: Del Prete M

Authors: Del Prete M, Di Sarno A, Ramundo V, Marciello F, Marotta V,

Keywords: pancreatic neuroendocrine tumors, CEUS, contrast enhancement, prognosis,